Allergic contact dermatitis of both eyes caused by alcaftadine 0.25%: a case report

Abstract Background To report the first case of allergic contact dermatitis (ACD) associated with alcaftadine 0.25% ophthalmic solution. Case presentation The patient was a 51-year-old woman with no previous history of side effects to ophthalmic antihistamine agents. She had been prescribed alcaftad...

Full description

Bibliographic Details
Main Authors: Jae Hyuk Kim, Hyun Joon Kim, Sun Woong Kim
Format: Article
Language:English
Published: BMC 2019-07-01
Series:BMC Ophthalmology
Subjects:
Online Access:http://link.springer.com/article/10.1186/s12886-019-1166-2
id doaj-9642043be4cc45bea1c24fc0e3965710
record_format Article
spelling doaj-9642043be4cc45bea1c24fc0e39657102020-11-25T03:38:38ZengBMCBMC Ophthalmology1471-24152019-07-011911410.1186/s12886-019-1166-2Allergic contact dermatitis of both eyes caused by alcaftadine 0.25%: a case reportJae Hyuk Kim0Hyun Joon Kim1Sun Woong Kim2Department of Ophthalmology, Wonju Severance Christian HospitalDepartment of Ophthalmology, Wonju Severance Christian HospitalDepartment of Ophthalmology, Wonju Severance Christian HospitalAbstract Background To report the first case of allergic contact dermatitis (ACD) associated with alcaftadine 0.25% ophthalmic solution. Case presentation The patient was a 51-year-old woman with no previous history of side effects to ophthalmic antihistamine agents. She had been prescribed alcaftadine 0.25% for allergic conjunctivitis. On first application of the medication, she did not experience any cutaneous reaction. One day later, after the second alcaftadine 0.25% application, both eyelids became swollen, and erythematous changes were evident. On slit-lamp examination, conjunctival injection was noted in the absence of conjunctival swelling or any other findings. Fundus examination was unremarkable. To evaluate the cause of ACD, a patch test was performed and 48 h later was noted to be positive for alcaftadine 0.25%. Based on the positive patch test, the patient was diagnosed with ACD caused by alcaftadine 0.25%. After 9 days of treatment, the swelling and erythema completely resolved. Conclusions Although there have been no previous reports of alcaftadine 0.25%-associated ACD, it should be suspected in patients with swelling and erythematous change of both eyes after using alcaftadine 0.25%.http://link.springer.com/article/10.1186/s12886-019-1166-2Alcaftadine 0.25%Allergic contact dermatitisAllergic conjunctivitis
collection DOAJ
language English
format Article
sources DOAJ
author Jae Hyuk Kim
Hyun Joon Kim
Sun Woong Kim
spellingShingle Jae Hyuk Kim
Hyun Joon Kim
Sun Woong Kim
Allergic contact dermatitis of both eyes caused by alcaftadine 0.25%: a case report
BMC Ophthalmology
Alcaftadine 0.25%
Allergic contact dermatitis
Allergic conjunctivitis
author_facet Jae Hyuk Kim
Hyun Joon Kim
Sun Woong Kim
author_sort Jae Hyuk Kim
title Allergic contact dermatitis of both eyes caused by alcaftadine 0.25%: a case report
title_short Allergic contact dermatitis of both eyes caused by alcaftadine 0.25%: a case report
title_full Allergic contact dermatitis of both eyes caused by alcaftadine 0.25%: a case report
title_fullStr Allergic contact dermatitis of both eyes caused by alcaftadine 0.25%: a case report
title_full_unstemmed Allergic contact dermatitis of both eyes caused by alcaftadine 0.25%: a case report
title_sort allergic contact dermatitis of both eyes caused by alcaftadine 0.25%: a case report
publisher BMC
series BMC Ophthalmology
issn 1471-2415
publishDate 2019-07-01
description Abstract Background To report the first case of allergic contact dermatitis (ACD) associated with alcaftadine 0.25% ophthalmic solution. Case presentation The patient was a 51-year-old woman with no previous history of side effects to ophthalmic antihistamine agents. She had been prescribed alcaftadine 0.25% for allergic conjunctivitis. On first application of the medication, she did not experience any cutaneous reaction. One day later, after the second alcaftadine 0.25% application, both eyelids became swollen, and erythematous changes were evident. On slit-lamp examination, conjunctival injection was noted in the absence of conjunctival swelling or any other findings. Fundus examination was unremarkable. To evaluate the cause of ACD, a patch test was performed and 48 h later was noted to be positive for alcaftadine 0.25%. Based on the positive patch test, the patient was diagnosed with ACD caused by alcaftadine 0.25%. After 9 days of treatment, the swelling and erythema completely resolved. Conclusions Although there have been no previous reports of alcaftadine 0.25%-associated ACD, it should be suspected in patients with swelling and erythematous change of both eyes after using alcaftadine 0.25%.
topic Alcaftadine 0.25%
Allergic contact dermatitis
Allergic conjunctivitis
url http://link.springer.com/article/10.1186/s12886-019-1166-2
work_keys_str_mv AT jaehyukkim allergiccontactdermatitisofbotheyescausedbyalcaftadine025acasereport
AT hyunjoonkim allergiccontactdermatitisofbotheyescausedbyalcaftadine025acasereport
AT sunwoongkim allergiccontactdermatitisofbotheyescausedbyalcaftadine025acasereport
_version_ 1724541425056481280